Garetosmab Demonstrates Sustained Efficacy in Adults With Fibrodysplasia Ossificans Progressiva (FOP) by Chad Birt| Published on: Nov 9, 2026

Garetosmab Demonstrates Sustained Efficacy in Adults With Fibrodysplasia Ossificans Progressiva (FOP) by Chad Birt| Published on: Nov 9, 2026 Richard Keen, MD, PhD, Director of the Metabolic Bone Disease Centre at the Royal National Orthopaedic Hospital in London and global principal investigator of the OPTIMA trial, discusses positive 84-week results from the phase 3 OPTIMA trial extension, evaluating Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP). https://checkrare.com/garetosmab-demonstrates-sustained-efficacy-in-adults-with-fibrodysplasia-ossificans-progressiva-fop/